Endocrine Abstracts

About 10–15% of prolactinomas (P) are resistant to Dopamine agonists (DA). We analyzed retrospectively ten resistant prolactinomas (RP) treated at our center between 1995 and 2014, to identify useful variables to predict DA resistance and its different patterns (biochemical resistance (BR), morphological resistance (MR) or both). BR is defined as the failure to normalize prolactin (PRL) levels with ≥ 2 mg/week of cabergoline (C) for at least 3 months. MR is consider...